GRK6 palmitoylation dictates triple-negative breast cancer metastasis via recruiting the β-Arrestin 2/MAPKs/NF-κB signaling axis
2024

GRK6's Role in Triple-Negative Breast Cancer Metastasis

Sample size: 116 publication 10 minutes Evidence: high

Author Information

Author(s): Wang Wen-Ke, Lin Hui-Yu, Lin Che-Hsuan, Lee Hsun-Hua, Chen Yen-Lin, Lin Yu-Hsien Kent, Chiu Hui-Wen, Sheen-Chen Shry-Ming

Primary Institution: Taipei Medical University

Hypothesis

The study investigates how GRK6 influences metastasis in triple-negative breast cancer (TNBC).

Conclusion

GRK6 upregulation is linked to increased metastasis in TNBC, suggesting it as a potential therapeutic target.

Supporting Evidence

  • GRK6 expression is significantly higher in TNBC compared to normal tissues.
  • Knockdown of GRK6 reduces migration ability of TNBC cells.
  • Overexpression of GRK6 enhances metastatic potential in TNBC cells.
  • GRK6's palmitoylation is critical for its function in promoting metastasis.
  • Inhibition of GRK6 activity suppresses TNBC cell migration.
  • GRK6 activates the β-Arrestin 2/MAPK/NF-κB signaling pathway.
  • High GRK6 levels correlate with poor prognosis in TNBC patients.

Takeaway

This study found that a protein called GRK6 helps triple-negative breast cancer spread to other parts of the body, and blocking it might help treat the cancer.

Methodology

The study used bioinformatics, RT-PCR, migration assays, and Western blotting to analyze GRK6's role in TNBC.

Participant Demographics

Participants included breast cancer patients with varying subtypes, specifically focusing on triple-negative cases.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/s13058-024-01953-z

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication